Teva Pharmaceutical (TEVA) shares remain in focus after the company secured U.S. Food and Drug Administration (FDA) approval for Weltruza as a treatment for schizophrenia in adults. Teva expects availability in the coming weeks, with no loading doses, supplemental oral treatment, or post-injection monitoring required.
Including the post-announcement rally, TEVA stock is up about 30% versus the start of this year.